Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05590468 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
A Phase 2 study of Mitochondrial Myopathy, sponsored by Ralitza Gavrilova.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05590468 is a Phase 2 study of Mitochondrial Myopathy that is active but no longer recruiting, run by Ralitza Gavrilova. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05590468, a Phase 2 study of Mitochondrial Myopathy, is active but no longer recruiting, sponsored by Ralitza Gavrilova.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Nicotinamide Riboside
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05590468
The ClinicalTrials.gov registry entry for NCT05590468 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ralitza Gavrilova, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitochondrial Myopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05590468 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05590468 about?
NCT05590468 is a clinical study titled "A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy". The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.
What is the current status of trial NCT05590468?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2023-05-26. Estimated completion is 2026-11.
What conditions does trial NCT05590468 study?
This clinical trial studies the following conditions: Mitochondrial Myopathy.
What interventions are being tested in trial NCT05590468?
The interventions under investigation include: Placebo (DRUG), Nicotinamide Riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05590468?
This trial is sponsored by Ralitza Gavrilova, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05590468 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Myopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.